2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. LDLR
  5. LDLR Inhibitor

LDLR Inhibitor

LDLR Inhibitors (14):

Cat. No. Product Name Effect Purity
  • HY-152857
    Muvalaplin
    		Inhibitor 99.96%
    Muvalaplin (LY3473329) is an orally active, selective small molecule inhibitor of lipoprotein (a) (Lp (a)) that disrupts the initial non-covalent interaction between apo(a) and apoB100, preventing the disulphide bond and Lp(a) formation. Muvalaplin reduces the levels of Lp (a) in transgenic mice and in cynomolgus monkeys.
  • HY-145001
    20-HC-Me-Pyrrolidine
    		Inhibitor
    20-HC-Me-Pyrrolidine is a potent Aster protein inhibitor with IC50s of 0.11 μM, 0.06 μM, and 0.71 μM for Aster-A, Aster-B, and Aster-C, respectively. 20-HC-Me-Pyrrolidine blocks the ability of Asters to bind and transfer cholesterol. 20-HC-Me-Pyrrolidine also inhibits the movement of low-density lipoprotein (LDL) cholesterol to the endoplasmic reticulum (ER).
  • HY-167873
    Habenariol
    		Inhibitor
    Habenariol is a substantial phenolic antioxidant activity that can be isolated from the freshwater orchid, Habenaria repens.
  • HY-109567
    Gemcabene
    		Inhibitor 99.91%
    Gemcabene (PD-72953), a first-in-class lipid-lowering agent, lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C) and lowers pro-inflammatory acute-phase protein, C-reactive protein (CRP), exerting anti-inflammatory activity.
  • HY-120651
    LDL-IN-2
    		Inhibitor ≥99.0%
    LDL-IN-2 (compound 3) is an antioxidant against copper mediated low-density lipoproteins (LDL) oxidation.
  • HY-P99793
    Orticumab
    		Inhibitor ≥99.0%
    Orticumab (MLDL1278A) is an antibody targeting to oxidized or malondialdehyde-modified lipoprotein (LDL). Orticumab specifically inhibits oxidized low-density lipoproteins (oxLDL). Orticumab involves in modulation of autoimmune responses against oxLDL, improves atherosclerosis in animal model. Orticumab also can be used for research of psoriasis improvement.
  • HY-109567A
    Gemcabene calcium
    		Inhibitor ≥98.0%
    Gemcabene calcium (PD-72953 calcium), a first-in-class lipid-lowering agent, lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C) and lowers pro-inflammatory acute-phase protein, C-reactive protein (CRP), exerting anti-inflammatory activity.
  • HY-P990143
    Anti-Mouse/Rat/Bovine VLDL-R Antibody (IgG-6A6)
    		Inhibitor
    Anti-Mouse/Rat/Bovine VLDL-R Antibody (IgG-6A6) is a mouse-derived IgG1, λ type antibody inhibitor, targeting to mouse/rat/Bovine VLDL-R.
  • HY-U00054
    LDL-IN-3
    		Inhibitor
    LDL-IN-3 is an anti-atherosclerotic compound extracted from patent WO/2005/039596A1, example C25 and patent US 6133467, example 3.
  • HY-113288
    Campestanol
    		Inhibitor ≥99.0%
    Campestanol is a phytosterol that can be found in plant food. Campestanol lowers serum cholesterol and low-density lipoprotein. Campestanol can be used for the research of metabolic disorders.
  • HY-167870
    Piceatannol 4'-O-glucoside
    		Inhibitor
    Piceatannol 4'-O-glucoside is an antioxidant. Piceatannol 4'-O-glucoside is active against oxidation of the human LDL. Piceatannol 4'-O-glucoside can be isolated from Mexican Bamboo.
  • HY-123260
    S12340
    		Inhibitor
    S12340 is a a inhibitor of the oxidative modification of low-density lipoprotein and shows protective effect on cardiac cells exposed to oxidative stress.
  • HY-138089
    17β-Hydroxy exemestane
    		Inhibitor
    17β-Hydroxy exemestane (17-H-EXE) is the primary active metabolite of Exemestane (HY-13632). 17β-Hydroxy exemestane is an aromatase inhibitor (IC50 = 69 nM) and an androgen receptor (AR) agonist (IC50 = 39.6 nM) that is selective for AR over estrogen receptor α (ERα; IC50 = 21.2 μM). 17β-Hydroxy exemestane stimulates growth of AR- and ERα-positive MCF-7 (EC50= 2.7 μM) and T47D breast cancer cells (EC50s = 0.43 and 1500 nM for AR- and ER-mediated growth, respectively) and inhibits proliferation of testosterone-treated aromatase-overexpressing MCF-7 cells. 17β-Hydroxy exemestane inhibits increases in serum cholesterol and LDL levels and prevents decreases in bone mineral density in the lumbar vertebrae and femur, as well as femoral bending strength and compressive strength of the fifth lumbar vertebrae in ovariectomized rats.
  • HY-165512
    Nicanartine
    		Inhibitor
    Nicanartine, an orally active antioxidant and lipid-lowering compound, is an antiatherogenic drug. Nicanartine inhibits the oxidation of low-density lipoprotein (LDL).